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AbsTrACT 
background it has been debated, but not yet 
established, whether increased airway responsiveness 
can predict cOPD. recognising this link may help in 
identifying subjects at risk.
Objective We studied prospectively whether airway 
responsiveness is associated with the risk of developing 
cOPD. 
Methods We pooled data from two multicentre 
cohort studies that collected data from three time 
points using similar methods (european community 
respiratory Health Survey and Swiss cohort Study on 
air Pollution and lung and Heart Diseases in adults). 
We classified subjects (median age 37 years, 1st–3rd 
quartiles: 29–44) by their level of airway responsiveness 
using quintiles of methacholine dose–response slope 
at the first examination (1991–1994). then, we 
excluded subjects with airflow obstruction at the second 
examination (1999–2003) and analysed incidence of 
cOPD (postbronchodilator FeV1/FVc below the lower 
limit of normal) at the third examination (2010–2014) 
as a function of responsiveness, adjusting for sex, age, 
education, body mass index, history of asthma, smoking, 
occupational exposures and indicators of airway calibre. 
results We observed 108 new cases of cOPD 
among 4205 subjects during a median time of 9 years. 
compared with the least responsive group (incidence 
rate 0.6 per 1000/year), adjusted incidence rate ratios 
for cOPD ranged from 1.79 (95% ci 0.52 to 6.13) 
to 8.91 (95% ci 3.67 to 21.66) for increasing airway 
responsiveness. Similar dose–response associations 
were observed between smokers and non-smokers, 
and stronger associations were found among subjects 
without a history of asthma or asthma-like symptoms. 
Conclusions Our study suggests that increased airway 
responsiveness is an independent risk factor for cOPD. 
Further research should clarify whether early treatment 
in patients with high responsiveness can slow down 
disease progression.
InTrOduCTIOn
Airway responsiveness is the ability of the airways 
to narrow when challenged with cold temperatures, 
aeroallergens or other noxious stimuli.1 2 In clinical 
practice, it is frequently assessed by measuring 
the relative decrease of FEV1 after the adminis-
tration of a constrictor agent, such as methacho-
line.3 Measurements of airway responsiveness are 
useful in diagnosing asthma since most patients 
have an abnormal reaction to airways irritants. 
High responsiveness is also a common trait among 
patients with COPD.4 It is associated with acceler-
ated lung function decline in smokers with early 
COPD,5 and it predicts disease progression, worse 
prognosis and mortality for COPD even among life-
time non-smokers.6 7 Nonetheless, the contribution 
of the presence and severity of airway responsive-
ness to the aetiology of COPD is still unclear.4 8 9
Recognising the direction of the association 
between airway responsiveness and COPD may 
help in better understanding the pathophysiology 
of the disease and eventually in identifying a clinical 
marker of disease risk or progression. It is accepted 
that, as the airway narrows, it becomes more 
responsive to irritants and bronchoconstrictors, 
and that this is at least in part due to the changing 
geometry of the airways. For this reason, it has long 
been assumed that, in subjects with COPD, airway 
responsiveness is a consequence of the structural 
and functional changes related to the disease.8 10 
Later evidence suggested that high responsiveness 
Key messages
What is the key question?
 ► Is airway responsiveness an independent risk 
factor for the development of COPD in the 
general population?
What is the bottom line?
 ► Young adults with high airway responsiveness 
are at greater risk for developing COPD in later 
life.
Why read on?
 ► This study analysed COPD incidence, defined 
using postbronchodilator lung function data, 
in large population samples followed up 
prospectively over 20 years.
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may precede lung function decline and airflow obstruction, and 
that it reflects the underlying inflammatory process.8 11–14 To our 
knowledge, only one population-based study15 has evaluated 
the relationship between airway responsiveness and COPD inci-
dence prospectively using postbronchodilator (BD) spirometry, 
as recommended for the diagnosis in clinical guidelines.16
In this prospective cohort study, carried out within the Ageing 
Lungs in European Cohorts project (https://www. alecstudy. 
org/), we aimed to assess whether increased airway responsive-
ness is a risk factor for COPD. We exploited the data collected 
in two large multicentre population-based studies, which share 
similar methods and a common longitudinal design with infor-
mation collected at three time points: the European Commu-
nity Respiratory Health Survey (ECRHS) and the Swiss Cohort 
Study on Air Pollution and Lung and Heart Diseases in Adults 
(SAPALDIA).
MeThOds
study population
ECRHS is an international cohort study on subjects from the 
general population aged 20–44 years at enrolment in 1991–
1993.17 At the first examination, a 20% random sample of 
participants in a postal screening took part in a clinical assess-
ment. Subjects were followed up in 1999–2002 (second exam-
ination)18 and 2010–2013 (third examination) (www. ecrhs. org). 
SAPALDIA is a Swiss multicentre population-based cohort study. 
At the first examination in 1991, random samples of subjects 
aged 18–60 years were examined.19 Subjects were followed up 
in 2001–2003 (second examination)20 and 2010–2011 (third 
examination) (http://www. sapaldia. ch/ en/). Ethical approval 
was obtained by all centres in both studies from the appropriate 
ethics committees and written consent was obtained from the 
participants. Only the centres that took part in all the three 
examinations were considered for the analyses.
Clinical measurements
At each time point, information on health and lifestyle was 
collected through detailed personal interviews, and pre-BD 
spirometry was performed. Subjects were advised to avoid 
using a β2-agonist or anticholinergic inhaler for 4 hours or oral 
medication (β2-agonist, theophylline or antimuscarinic) for 
8 hours before the test. The maximum FEV1 and FVC, from at 
least two technically satisfactory manoeuvres, were measured 
according to the American Thoracic Society criteria for repeat-
ability.21 At the third examination, post-BD lung function using 
200 µg salbutamol was also measured in all the centres, except 
for Verona and Torino (ECRHS centres). Biomedin or Sensor-
Medics spirometers were used in most centres at the first and 
second examinations, whereas NDD EasyOne was used in almost 
all centres at the third examination (online supplementary Table 
E1). In SAPALDIA, which used SensorMedics at the first and 
second examinations and NDD EasyOne at the third examina-
tion, lung function data corrected for change in spirometer were 
used.22 The lower limit of normal (LLN) for the FEV1/FVC ratio 
was calculated using the reference equations by Quanjer et al.23
At the second examination, serum levels of total and specific 
IgE for house dust mite, cat and grass pollen were measured. 
Allergen sensitisation was considered present when specific IgE 
for at least one allergen were above 0.35 kU/L.
Airway challenge tests
Methacholine challenge tests were performed in both studies at 
the first and second examinations according to a similar protocol, 
which included standardised training for fieldworkers and 
monthly calibrations of the nebulisers.2 19 Briefly, subjects with 
an FEV1 greater than 70% of predicted and greater than 1.5 L 
were invited to undergo challenge tests, unless they reported 
they had heart disease, epilepsy, were pregnant, breast feeding or 
taking a beta blocker. After a control FEV1 manoeuvre following 
inhalation of saline diluent, methacholine chloride was admin-
istered by a Mefar aerosol dosimeter at progressing levels. FEV1 
was recorded 2 min after each inhalation and, in the absence of a 
20% fall in FEV1 from control value, the next dose was given up 
to a cumulative dose of 2 mg (8.37 µmol), except for the ECRHS 
centres of Barcelona, Albacete, Oviedo, Huelva (Spain), Ipswich 
and Norwich (UK), where the maximum dose was 1 mg.2 In 
order to obtain comparable indicators of responsiveness across 
centres, we excluded these centres from the analyses.
At each time point (first and second examinations), we derived 
a dose–response slope for each subject, which is called slope 
hereafter, following the ‘two-point’ method by O’Connor et 
al.24 The two-point slope was already available for SAPALDIA, 
and we used the same method in ECRHS for consistency. The 
slope was defined as the ratio between the percentage decline 
in FEV1 from the control value and the total cumulative dose 
of methacholine (% × µmol−1). As previously done in order to 
avoid negative slopes, the control value was replaced with the 
maximum FEV1 over all levels tested when control FEV1 did not 
correspond to maximum FEV1
25.
design of the analysis
In the main analysis, we used the slope measured at the first 
examination, categorised by quintiles of the distribution as 
done previously,14 as the main indicator of airway responsive-
ness, excluded subjects with a pre-BD FEV1/FVC ratio below the 
LLN at the second examination and then assessed the outcomes 
during the time between the second and third examinations (the 
follow-up period) (figure 1). We adopted this design in order to 
minimise reverse causation (ie, airflow obstruction causing an 
increase in airway responsiveness) by removing, at the beginning 
of the follow-up period, the subjects with airflow obstruction, 
who may have had an early form of COPD that was still not 
evident at the time of challenge tests.
Outcome definitions
The main outcome of the analysis was the incidence of COPDLLN, 
defined spirometrically as a post-BD FEV1/FVC <LLN at the 
third examination (after excluding those with a pre-BD FEV1/
FVC <LLN at the second examination). Further outcomes were 
absolute FEV1 decline (ΔFEV1) and percent change in FEV1 rela-
tive to baseline value (ΔFEV1%) between the second and third 
examinations, calculated using pre-BD lung function (post-BD 
spirometry was not available at the second examination) as 
follows:
1. ΔFEV1 (mL/year) = (FEV1 at 2
nd exam − FEV1 at 3
rd exam)/
time;
2. ΔFEV1% (%/year)=100 × [(FEV1 at 2
nd exam − FEV1 at 3
rd 
exam)/FEV1 at 2
nd exam]/time.
Potential confounders
The multivariable analyses were adjusted for sex; education level 
(low if completed before age 16); FEV1 predicted at the time 
of the challenge test (to account for differential deposition of 
methacholine in the lungs according to the airway calibre)26; age 
and body mass index (BMI, calculated as weight (kg) divided by 
squared height (m)) at the second examination (mean centred); 
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history of asthma/asthma-like symptoms (reporting asthma 
in lifetime; or reporting wheezing/whistling without a cold or 
having been woken by an attack of shortness of breath in the 
last 12 months) at the second or third examinations; history 
of active smoking over lifetime (coded as non-smoker at both 
examinations, ex-smoker at both examinations, smoker at the 
last examination with <28 pack-years (the median), smoker at 
the last examination with ≥28 pack-years, quitter); history of 
second-hand smoking, and occupational exposure to vapours, 
dust, gas or fumes at the second or third examination (both 
coded as never exposed, exposed only at one examination, 
exposed at both examinations). BMI2 at the second examina-
tion and ΔBMI (change in BMI between the second and third 
examination divided by time) were also included in the analysis 
of FEV1 decline.
27
statistical analysis
The statistical analyses were performed using STATA soft-
ware, V.14.2 (StataCorp, College Station, Texas, USA). We 
conducted pooled analyses of the ECRHS and SAPALDIA data 
since the number of cases of COPDLLN was small and there 
was no heterogeneity between studies (which was tested using 
Wald tests on interaction terms between slope and study). All 
the pooled analyses were adjusted for study (ECRHS vs SAPA-
LDIA). We also reported the results of the main analysis strat-
ified by study. Incidence of COPD was analysed using Poisson 
regression models with log person-years at risk as the offset. 
Centre was considered as a clustering factor and cluster-ro-
bust standard errors were used (multilevel modelling was not 
feasible because of data sparseness). ΔFEV1 and ΔFEV1% were 
analysed through two-level linear regression models, with a 
random intercept for centre (which significantly improved 
model fitting according to likelihood ratio tests). Missing data 
were deleted listwise.
We assessed effect modification by history of active smoking 
(lifetime never smokers: n=1839 vs ever smokers: n=2216), 
history of asthma/asthma-like symptoms (absent: n=3223 vs 
present: n=969) and sex, using stratified analyses and testing 
interaction terms by Wald tests.
sensitivity analyses
1. Outcomes
We analysed the incidence of:
1.1. COPDclinical, defined as a combination of a post-BD 
FEV1/FVC <LLN with at least one key indicator for COPD 
identified by the GOLD guidelines16: (a) history of symp-
toms (dyspnoea, chronic cough/sputum production); (b) 
history of smoking (≥10 pack-years) or occupational expo-
sures; (c) family history of COPD or early life risk factors 
(see online supplement);
1.2. COPD0.70, defined spirometrically as a post-BD FEV1/
FVC ratio <0.70 at the third examination (after excluding 
those with pre-BD FEV1/FVC ratio <0.70 at the second ex-
amination).15
Figure 1 Number of subjects included in the analyses by study. BD, bronchodilator; EC, European Community Respiratory Health Survey; LLN, lower 
limit of normal; SAP, Swiss Cohort Study on Air Pollution and Lung and Heart Diseases in Adults. 
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We replicated the main analysis on COPDLLN:
2. Airway responsiveness
2.1. Analysing the mean slope between the first and second 
examinations;
2.2. Analysing the ‘least-squares’ slope at the first examina-
tion, available for ECRHS2 (see online supplement).
3. Medication
3.1. Excluding the subjects who had used inhalers in the 
12 hours before any examination (41 in ECRHS and 42 in 
SAPALDIA);
3.2. Further adjusting for current use of inhaled/oral medi-
cation for asthma at the first examination (inhalers, aerosols 
or tablets for asthma) in the analysis on subjects with asthma/
asthma-like symptoms.
4. Adjustment variables
4.1. Adjusting for measured FEV1 (which replaced predicted 
FEV1 as an indicator of airway calibre);
4.2. Further adjusting, in separate models, for second-hand 
smoking in childhood, serious respiratory infections before 
the age of 5 (early-life risk factors for COPD), high total 
serum IgE (>100 kU/L) and allergen sensitisation (indicators 
of atopy).
resulTs
Overall, data on subjects from 25 centres in 10 countries were 
available. Among 14 089 subjects who had the slope available 
at the first examination (median age 37; 1st, 3rd quartiles (Q1, 
Q3): 29, 44 years), 10 825 subjects participated in the second 
examination (figure 1). Participants had an older median age (38 
vs 34 years, P<0.001), were more likely to be women (49.4 vs 
46.4%, P=0.002) and less likely to be a current smoker (32.4 vs 
41.7%, P<0.001) and to have asthma (7.2 vs 8.7%, P=0.004). 
Of these, 2326 were excluded because they had no lung function 
data, and 733 subjects (median slope 1.88, Q1–Q3: 1.11–5.78) 
were excluded because they had airflow obstruction (pre-BD 
FEV1/FVC ratio <LLN) at the second examination.
Of the remaining 7766 eligible subjects, 5756 (74%) took part 
in the third examination, and 4716 had lung function measured 
and were included in the analysis of FEV1 decline (figure 1). 
The median follow-up time was 9 (Q1, Q3: 8, 11) years. The 
slope distribution was similar between ECRHS and SAPALDIA: 
medians (Q1–Q3) were 0.9 (0.5–1.7) and 0.9 (0.5–1.5)% × 
µmol−1, respectively (P=0.27). At the second examination, 
subjects from ECRHS (n=2042) and SAPALDIA (n=2674) had 
a median age of 44 (Q1, Q3: 37, 49) years and 50 (Q1, Q3: 
41, 58) years, respectively. Compared with the subjects excluded 
from the analysis, the subjects included were younger and were 
less likely to have a low education, be a current smoker, report 
occupational exposures and have asthma (table 1).
Airway responsiveness and FeV1 decline
FEV1 at baseline ranged between 3.77 L and 3.22 L for subjects 
with the lowest to the highest airway responsiveness, respectively 
(P<0.001) (table 2). ΔFEV1 did not vary as a function of the 
slope (P=0.20), whereas the mean ΔFEV1% ranged from 1.04 to 
1.17 %/year (P<0.001), indicating an accelerated FEV1 decline 
for increasing responsiveness relative to the baseline value, but 
not in absolute terms. The adjusted analyses showed consistent 
results (online supplementary table E2).
Airway responsiveness and COPd
After excluding the centres where post-BD spirometry was not 
carried out (Verona and Torino), 4205 subjects were included 
in the analysis of the incidence of COPDLLN (figure 1). The 
mean±SD BD response was 88±128 mL for FEV1 and −3±172 
for FVC. Incident cases of COPDLLN at the third examination 
were 108 (49 in ECRHS and 59 in SAPALDIA).
The analyses showed clear dose–response associations between 
airway responsiveness and the risk of developing COPDLLN. The 
incidence rates ranged between 0.6 and 5.3 per 1000/year for 
increasing levels of responsiveness (P<0.001) (table 2). With 
respect to the least responsive group, incidence rate ratios (IRRs) 
adjusted for the potential confounders ranged from 1.79 (95% 
CI 0.52 to 6.13) to 8.91 (95% CI 3.67 to 21.66) for increasing 
responsiveness (figure 2). There was no heterogeneity of associa-
tions between studies (P interaction 0.27) (online supplementary 
table E3).
We found no significant interaction between history of 
smoking and airway responsiveness on COPDLLN (P for inter-
action 0.67). Subjects without and with asthma/asthma-like 
symptoms had a median slope of 0.9 (Q1–Q3: 0.5–1.4) and 1.2 
(Q1–Q3: 0.7–2.7)% × µmol−1, respectively (P<0.001). Asso-
ciations between slope and COPDLLN risk were stronger among 
the former compared with the latter groups (P for interaction 
0.02) (figure 3). IRRs were similar for men and women (P for 
interaction 0.84).
All the sensitivity analyses confirmed a dose–response relation-
ship between airway responsiveness and COPD risk. Association 
Table 1 Characteristics of the subjects excluded and included in the 
analyses*
Characteristics
excluded
(n=3050)
Included
(n=4716) P value†
Female sex, n (%) 1546 (50.7) 2327 (49.3) 0.25
Age, mean±SD (years) 47.6±11.0 46.9±9.9 0.003
Body mass index, mean±SD (kg/m2) 25.6±4.4 25.3±4.0 0.006
Low education, n (%) 302 (9.9) 269 (5.7) <0.001
Smoking habits, n (%) <0.001 
Non-smoker 1298 (42.7) 2186 (46.6) 
Ex-smoker 855 (28.1) 1461 (31.1) 
Current smoker 887 (29.2) 1049 (22.3) 
Second-hand smoking, n (%) 955 (31.4) 1313 (27.9) 0.001
Past/current occupational exposure 
to vapours, gas, dusts or fumes, 
n (%)
1343 (44.5) 1947 (41.8) 0.020
Ever asthma, n (%) 291 (9.6) 368 (7.8) 0.007
High total serum IgE
(>100 kU/L), n (%)
577 (20.5) 850 (18.9) 0.107
Allergen sensitisation‡, n (%) 722 (24.8) 1160 (25.2) 0.70
FEV1, mean±SD (L) 3.41±0.83 3.51±0.79 <0.001
%FEV1/FVC, mean±SD 79.3±6.0 79.0±5.8 0.043
Slope, median (Q1–Q3) (% per 
µmol)
1.0 (0.6–1.7) 0.9 (0.5–1.6) <0.001
*All characteristics were measured at the second examination except for the slope 
(assessed at the first examination); subjects were excluded from the analyses 
either if they did not participate in the third examination (n=2010) or if they had 
no prebronchodilator lung function data available (n=1040). Percentages were 
calculated on subjects with data available for each variable.
†Obtained using Pearson’s χ2 test (categorical variables), Kruskal-Wallis rank test 
(slope) or ANOVA (the remaining variables).
‡In the Swiss Cohort Study on Air Pollution and Lung and Heart Diseases in Adults, 
specific IgE were only measured for subjects with a positive (>0.35 kU/L) Phadiatop 
Test (Phadia, Uppsala, Sweden); subjects with a negative test were assigned to the 
group with no sensitisation.
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estimates for COPDclinical and COPD0.70 (incident cases: 93 and 
242, respectively) are reported in table 3. Results from the anal-
yses using alternative indicators of responsiveness are shown in 
online supplementary table E4. When adjusting for measured 
FEV1, IRRs for COPDLLN ranged from 1.42 (95% CI 0.45 to 4.44) 
for subjects with a slope at the first examination of 0.44–0.73% 
× µmol−1, to 5.77 (95% CI 2.95 to 11.26) for subjects with a 
slope ≥1.84% × µmol−1. Use of asthma medication at the first 
examination was more frequent for subjects with slope ≥1.84% 
× µmol−1 (10%) compared with the other groups (between 1% 
and 2%). Associations were consistent when further adjusting 
for use of asthma medication (online supplementary table E5) 
and when using alternative sets of adjustment variables (data not 
shown).
dIsCussIOn
We analysed data from two multicentre population-based cohort 
studies with similar designs and study protocols. The analyses 
showed that higher airway responsiveness measured during 
young adult life was prospectively associated with an increased 
risk of COPD 20 years later.
Compared with previous literature,11 14 28 29 our study adds 
stronger prospective evidence that increased responsiveness can 
precede the development of COPD. In fact, we derived indi-
cators of responsiveness in young adulthood (1991–1994), 
Figure 2 Incidence rate ratios (IRRs) with 95% CIs for the association 
between increasing airway responsiveness and the development 
of COPDLLN (Airway responsiveness according to the slope at the 
first examination, with slope <0.44% × µmol−1 as the reference 
category. Adjusted for study, sex, education, FEV1 predicted, age, body 
mass index, history of asthma/asthma-like symptoms, history of active 
smoking, second-hand smoking and occupational exposures to vapours, 
gas, dusts or fumes. Number of subjects: 3747. The y-axis is on log2 
scale).
Figure 3 Incidence rate ratios (IRRs) with 95% CIs for the association 
between increasing airway responsiveness and the development of 
COPDLLN, stratified by history of smoking (top panels), and history of 
asthma/asthma-like symptoms (bottom panels) (Airway responsiveness 
according to the slope at the first examination, with slope <0.44% × 
µmol-1 as the reference category. Adjusted for study, sex, education, 
FEV1 predicted, age, body mass index, second-hand smoking and 
occupational exposures to vapours, gas, dusts or fumes. Also adjusted 
for history of asthma/asthma-like symptoms, history of active smoking 
(when these are not used for stratification) and for lifetime pack-years 
(only analysis on smokers, top right panel; data on pack-years not 
available for 133 subjects). Number of subjects: never smokers, 1670; 
smokers, 1944; without asthma/asthma-like symptoms, 2890; with 
asthma/asthma-like symptoms, 852. Pint is the P value for the interaction 
between slope group and stratification variable. The y-axis is on log2 
scale).
Table 2 Mean absolute FEV1 (at the second examination), mean lung function decline and incidence rates of COPD (between the second and third 
examinations) for increasing airway responsiveness, with 95% CIs, adjusted only for study
Outcomes
FeV1 at the 2nd 
examination (l)
ΔFeV1
(ml/year)
ΔFeV1%
(%/year)
Incidence of COPdlln
(per 1000/year)
number of subjects 4716 4716 4716 4205
Slope group, by quintiles
(% × µmol−1)
<0.44
0.44–0.73
0.74–1.12
1.13–1.84
≥1.84
3.77 (3.70 to  3.84)
3.68 (3.61 to  3.74)
3.49 (3.42 to  3.56)
3.35 (3.29 to  3.42)
3.22 (3.15 to  3.28)
38.8 (35.1 to  42.5)
38.6 (34.9 to  42.3)
37.0 (33.3 to  40.7)
38.5 (34.8 to  42.3)
36.3 (32.6 to  40.0)
1.04 (0.94 to  1.14)
1.06 (0.96 to  1.16)
1.07 (0.97 to  1.17)
1.17 (1.08 to  1.27)
1.17 (1.07 to  1.27)
0.6 (0.1 to  1.1)
1.1 (0.6 to  1.6)
2.3 (1.0 to  3.5)
3.8 (2.4 to  5.1)
5.3 (3.2 to  7.5)
Overall P value <0.001 0.20 <0.001 <0.001
LLN, lower limit of normal.
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excluded subjects who had airflow obstruction a decade after 
(1999–2003) and then assessed the outcomes during the last 
available follow-up period (up to 2010–2013). This design 
makes it less likely that an early, slowly progressing or undetected 
form of COPD can be the main explanation for high respon-
siveness observed at the first examination. COPD was defined 
using post-BD spirometry, and similar conclusions were obtained 
when using the LLN cut-off for the FEV1/FVC ratio, as advo-
cated by the European Respiratory Society,30 or when using the 
fixed cut-off of 0.70, as recommended by clinical guidelines.16 
Also, conclusions were similar when using a definition of COPD 
that combined post-BD airflow obstruction with key indicators 
for diagnosis in clinical practice.16 A strength of this study is the 
use of continuous indicators of airway responsiveness. Unlike 
the PD20 or similar censored indicators, the slope can be derived 
for all individuals, entailing the concept of responsiveness as 
a continuous trait, and it is able to recognise lower levels of 
responsiveness.14
The slope at the first examination was prospectively associ-
ated both with a lower lung function (pre-BD spirometry) at 
the second examination and with a higher incidence of COPD 
(post-BD spirometry) at the third examination, suggesting that a 
high responsiveness is associated with increased bronchospasm 
and also with the development of fixed obstruction.31 Subjects 
with a higher slope did not have a steeper absolute FEV1 decline 
(mL/year) compared with less responsive individuals, suggesting 
that an impairment in lung function must have occurred earlier 
in these individuals, possibly due to lower attained lung func-
tion, an early loss at young ages or both.4 32–34
Some previous studies using pre-BD spirometry reported that 
smoking may modify the association of airway responsiveness 
with lung function decline28 and COPD risk.11 In our study, asso-
ciations were not significantly different for smokers compared 
with non-smokers. Since we had a low number of COPD cases, 
our analysis may have been underpowered to test effect modi-
fication (indeed we were only able to test interactions using a 
binary indicator of smoking that did not take pack-years into 
account). It is also possible that other factors, such as reduced 
participation among smokers, can explain the lack of a signifi-
cant interaction, or that findings from previous studies were due 
to the lack of post-BD lung function measurements. Regardless 
of the existence of a ‘true’ interaction between smoking and 
responsiveness, it is reasonable to think that (since smoking is 
a modifiable risk factor that adds to the baseline risk in subjects 
with a high responsiveness) smokers with high responsiveness 
may particularly benefit from smoking cessation advice.
A higher responsiveness at the first examination was a risk 
factor for COPD both in subjects who reported asthma and in 
subjects who reported neither asthma nor asthma-like symptoms 
(which may have indicated undiagnosed asthma) for the 20 years 
following challenge testing. A different strength of the associa-
tions between the two groups (P for interaction 0.02) may be 
related to a different pathophysiological role of airway respon-
siveness. In subjects with asthma, responsiveness may be an indi-
cator of asthma activity, severity of inflammation and airway 
remodelling. In subjects without asthma, responsiveness may 
affect the risk of COPD through pathways that are unrelated 
(not mediated) by the development of asthma.
One limitation of our study is that different types of spirom-
eters were used at different time points. This may have intro-
duced some bias if any systematic measurement error was 
differential across slope groups. However, we found consistent 
associations in the analysis restricted to SAPALDIA, where lung 
function measurements were corrected for change in spirom-
eter.22 Due to the challenges of following up individuals over 
20 years, our study had substantial attrition, especially among 
smokers and subjects with asthma. Selection bias can especially 
distort estimates of disease frequency; however, it is less likely to 
strongly bias association estimates.35 We used pre-BD lung func-
tion to exclude prevalent cases of COPD, which seems adequate 
for epidemiological purposes as only one out of 100 subjects 
without pre-BD obstruction has COPD (negative predictive 
value of 99%).36 Finally, we used the two-point slope because 
it is easier to interpret compared with the least-squares slope, 
which was developed in ECRHS to account for systematic differ-
ences in the dose delivered by different Mefar nebulizers, and 
could be more suitable in multicentre settings.1 2 Nonetheless, 
the results were consistent when using the least-squares slope.
COnClusIOns
Our study suggests that increased airway responsiveness precedes 
and is an independent risk factor for COPD. An increased risk 
of COPD was also evident for intermediate levels of the slope 
corresponding to a moderate responsiveness. In clinical prac-
tice, it would be desirable to intervene in the early stages of 
COPD before the level of airflow obstruction contraindicates 
airway challenge tests. Our findings suggest that measuring 
airway responsiveness could help in identifying subjects at risk 
for COPD, and they prompt further research on whether early 
treatment of patients with high responsiveness can slow down 
disease progression.37
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